LSC
TEVA icon

Lesa Sroufe & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Lesa Sroufe & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-102,468
Closed -$1.61M – 63
2019
Q1 		$1.61M Sell
102,468
-10,825
-10% -$191K 1.37% 33
2018
Q4 		$1.75M Sell
113,293
-3,550
-3% -$72.8K 1.49% 30
2018
Q3 		$2.52M Sell
116,843
-25
-0% -$580 1.89% 30
2018
Q2 		$2.84M Buy
116,868
+8,860
+8% +$181K 2.09% 29
2018
Q1 		$1.85M Buy
108,008
+6,675
+7% +$130K 1.45% 31
2017
Q4 		$1.92M Sell
101,333
-2,287
-2% -$34.4K 1.59% 28
2017
Q3 		$1.82M Sell
103,620
-2,765
-3% -$62.2K 1.6% 27
2017
Q2 		$3.53M Buy
106,385
+1,556
+1% +$48.2K 3.28% 19
2017
Q1 		$3.36M Buy
+104,829
New +$3.58M 3.08% 19
2014
Q3 		– Sell
-163,218
Closed -$8.56M – 43
2014
Q2 		$8.56M Buy
163,218
+922
+0.6% +$47.1K 4.34% 5
2014
Q1 		$8.58M Sell
162,296
-1,795
-1% -$83K 4.66% 4
2013
Q4 		$6.58M Sell
164,091
-1,367
-0.8% -$53.8K 3.58% 14
2013
Q3 		$6.25M Buy
165,458
+13,006
+9% +$507K 3.63% 14
2013
Q2 		$5.98M Buy
+152,452
New +$5.94M 3.45% 12

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lesa Sroufe & Co's TEVA Position: Q2 2019 in Review

Lesa Sroufe & Co sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 102,468 shares — an estimated $1.61M sold.

Lesa Sroufe & Co first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $8.58M in Q1 2014. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Lesa Sroufe & Co reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Lesa Sroufe & Co sold 102,468 Teva Pharmaceuticals shares in Q2 2019, an estimated $1.61M.
  • Lesa Sroufe & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Lesa Sroufe & Co's Teva Pharmaceuticals position peaked at $8.58M in Q1 2014.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Lesa Sroufe & Co's 13F filing for Q2 2019, filed 29 Jul 2019.